NASDAQ
27.06.25 | 21:59
0,421 US-Dollar
-6,98 % -0,032
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 4 | Investing.com Deutsch | ||
| 12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 3 | Investing.com | ||
| 20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 136 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
| 13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 302 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | What's Next: ALX Oncology Holdings' Earnings Preview | 1 | Benzinga.com | ||
| 02.05. | ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | 3 | GlobeNewswire (USA) | ||
| 25.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | 1 | FierceBiotech | ||
| 25.04. | ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma | 174 | GlobeNewswire (Europe) | - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated... ► Artikel lesen | |
| 25.04. | ALX Oncology falls on mid-stage trial setback for lead asset | 1 | Seeking Alpha | ||
| 25.04. | ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints | 197 | GlobeNewswire (Europe) | In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains... ► Artikel lesen | |
| 08.04. | ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours | 1 | Pharmaceutical Business Review | ||
| 07.04. | ALX Oncology gets FDA clearance to begin trial of ALX2004 | 3 | Seeking Alpha | ||
| 07.04. | ALX Oncology bringt neues Krebsmedikament in Phase-1-Studien | 2 | Investing.com Deutsch | ||
| 07.04. | ALX Oncology advances new cancer drug into Phase 1 trials | 2 | Investing.com |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,138 | -0,81 % | EQS-News: Evotec SE: Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis von akutem Nierenversagen | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotecs Partnerschaft mit dem NURTuRE-AKI Konsortium ermöglicht innovative therapeutische Ansätze basierend auf molekularem Verständnis... ► Artikel lesen | |
| MODERNA | 23,305 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
| CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
| DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
| EDITAS MEDICINE | 1,924 | -1,00 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
| BIOMARIN PHARMACEUTICAL | 47,060 | -0,17 % | BioMarin Presents Long-term Efficacy And Safety Of Roctavian | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Tuesday announced new data underscoring the long-term efficacy and safety of Roctavian (valoctocogene roxaparvovec-rvox).The Phase... ► Artikel lesen | |
| EXELIXIS | 37,080 | -0,59 % | ROUNDUP/Aktien New York: Entspannt nach US-Militärschlag und positiven Daten | NEW YORK (dpa-AFX) - Angesichts der bislang überschaubaren ökonomischen Auswirkungen des US-Militärschlags gegen den Iran sind die Anleger an den US-Börsen am Montag recht gelassen geblieben. Zudem... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 108,55 | +1,26 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ... | Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia
Findings... ► Artikel lesen | |
| EXACT SCIENCES | 46,740 | +1,95 % | Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,421 Euro und damit -6,98 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.